Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06401356 · ClinicalTrials.gov registry record · Phase 3
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
A Phase 3 study of Solid Tumor and Hematologic Malignancy, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 15
- Study locations
NCT06401356: Recruiting Phase 3 study of Solid Tumor and Hematologic Malignancy, sponsored by Novartis Pharmaceuticals.
NCT06401356 is a Phase 3 study of Solid Tumor and Hematologic Malignancy that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 50 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (77% lower). The trial reports 15 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06401356, a Phase 3 study of Solid Tumor and Hematologic Malignancy, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).
Primary Outcome
To evaluate long-term safety in patients who are receiving pelabresib
Conditions Studied
Interventions
- DRUG Pelabresib
Study Locations (15)
Other
- ZNA Cadix-Hematology - Antwerp
- Az St-Jan Brugge-Oostende A.V. - Bruges
- AOU Careggi (Department of Experimental and Clinical Medicine) - Florence
- Azienda Ospedaliero - Universitaria Maggiore della Carità (SCDU Ematologia) - Novara
- AO Ospedale di Circolo, PO Varese (Ematologia) - Varese
- Amsterdam UMC location Vumc (Hematology) - Amsterdam
- Cardiff and Vale University Health Board - University Hospital Wales (Hematology) - Cardiff
- Beatson West of Scotland Cancer Centre (Hematology) - Glasgow
- Guys and St Thomas' Hospital - Haematology - London
New York
- Mount Sinai Hospital - Oncology - New York
- Weill Cornell Medicine - New York Presbyterian Hospital (Oncology) - New York
California
- Hematologic Malignancy/Stem (Department of Medicine, Division of Hematology/Oncology) - Los Angeles
Florida
- Mayo Clinic (Cancer Clinical Research Office) - Jacksonville
Illinois
- Northwestern Memorial Hospital (Oncology) - Chicago
Michigan
- UMHS - University of Michigan Medical Center (Radiation Oncology) - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-08-13 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
What NCT06401356 shows while recruiting
NCT06401356 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (77% lower).
The record links to 3 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Pelabresib is the first listed.
NCT06401356 lists 15 locations in 6 states (Other, New York, California).
Frequently Asked Questions
What is clinical trial NCT06401356 about?
NCT06401356 is a clinical study titled "An Extension Study for Patients Previously Enrolled in Studies With Pelabresib". The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants ...
What is the current status of trial NCT06401356?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2024-08-13. Estimated completion is 2027-06-30.
What conditions does trial NCT06401356 study?
This clinical trial studies the following conditions: Solid Tumor, Hematologic Malignancy, Advanced Malignancies.
What interventions are being tested in trial NCT06401356?
The interventions under investigation include: Pelabresib (DRUG).
Who is sponsoring clinical trial NCT06401356?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06401356 being conducted?
This trial has 15 study locations across California, Florida, Illinois, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06401356's enrollment target sits among peer trials
50 122nd of 196 higher than 71 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI